The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy
- PMID: 17277727
The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy
Abstract
Objective: Prostate cancer is now recognized as one of the principal medical problems facing male population and the commonest cancer in males in delevoped countries. The aim of this study was to find out whether serum hormone levels differ significantly in localized (pT2) and locally advanced (pT3-pT4 or N1) prostate cancer.
Methods: In 250 men (mean age+/-SEM: 63.8+/-0.4) who underwent radical retropubic prostatectomy for histologically confirmed prostate cancer were analyzed serum samples for total testosterone, dehydroepiandrosterone sulfate, estradiol, progesterone, prolactin, cortisol, sex hormone-binding globulin, luteinizing hormone and follicle stimulating hormone. Free testosterone content was calculated from total testosterone and SHBG concentrations.
Results: Significantly lower serum level of FSH, i.e. 5.63+/-0.31 vs. 7.07+/-0.65 U/L was found in patients with localized prostate cancer than in locally advanced (p<0.05). Significant correlation was found between serum levels of DHEAS and cortisol in both groups (p<0.02), estradiol and prolactin in patients with locally advanced prostate cancer, as well between LH and prolactin (p<0.05). No differences were found in other observed hormones.
Conclusion: The results point to importance of hormone status as possible additional prognostic marker for patients with prostate cancer. Considerable research is needed to further understand influence of hormones on prostate cancer.
Similar articles
-
Influence of radical prostatectomy on serum hormone levels.J Urol. 1998 Aug;160(2):449-53. J Urol. 1998. PMID: 9679896
-
[Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].Hell J Nucl Med. 2007 Jan-Apr;10(1):56-61. Hell J Nucl Med. 2007. PMID: 17450256 Clinical Trial. Greek, Modern.
-
Radical prostatectomy: influence on serum and urinary androgen levels.Prostate. 2010 Feb 1;70(2):200-5. doi: 10.1002/pros.21053. Prostate. 2010. PMID: 19760638
-
Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.J Urol. 2004 Sep;172(3):920-2. doi: 10.1097/01.ju.0000136269.10161.32. J Urol. 2004. PMID: 15310998 Review.
-
Control of prostate growth.Urology. 1981 Mar;17(Suppl 3):17-24. Urology. 1981. PMID: 6163242 Review. No abstract available.
Cited by
-
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.Prostate. 2010 Mar 1;70(4):443-55. doi: 10.1002/pros.21078. Prostate. 2010. PMID: 19902470 Free PMC article.
-
The Biochemical Effects of Silver Nanoparticles and Spirulina Extract on Experimentally Induced Prostatic Cancer in Rats.Biol Trace Elem Res. 2023 Apr;201(4):1935-1945. doi: 10.1007/s12011-022-03298-0. Epub 2022 Jun 11. Biol Trace Elem Res. 2023. PMID: 35689758 Free PMC article.
-
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.Asian J Androl. 2022 Jan-Feb;24(1):21-25. doi: 10.4103/aja.aja_58_21. Asian J Androl. 2022. PMID: 34259197 Free PMC article.
-
Experience with degarelix in the treatment of prostate cancer.Ther Adv Urol. 2013 Feb;5(1):11-24. doi: 10.1177/1756287212461048. Ther Adv Urol. 2013. PMID: 23372607 Free PMC article.
-
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.Ther Adv Urol. 2016 Apr;8(2):75-82. doi: 10.1177/1756287215621471. Epub 2015 Dec 16. Ther Adv Urol. 2016. PMID: 27034720 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous